Dr. Lombard received his MD from Harvard Medical School, and his PhD from MIT, focused on Werner syndrome and related progerias. After Pathology residency, Dr. Lombard pursued postdoctoral work in Dr. Fred Alt’s laboratory (HHMI/The Children’s Hospital, Boston MA), where he studied the sirtuins SIRT3 and SIRT6, supported by an NIA/NIH K08 award. Dr. Lombard was the first to describe a central role for SIRT3 in regulating mitochondrial protein acetylation. Subsequent studies have revealed that SIRT3 is a major player in regulating metabolism, cancer, the pro-longevity calorie restriction response, and cardioprotection. He set up his independent lab at the University of Michigan in 2008. Among Dr. Lombard’s most significant recent contributions have been carrying out small molecule screens for induction of cellular stress resistance (Science Advances); describing SIRT5’s oncogenic function in melanoma (JCI); and novel aspects of mitochondrial regulation by SIRT5 (Molecular Cell). He is a member of the Aging Cell and JBC editorial boards. He was named a New Scholar in Aging of the Ellison Medical Foundation, a member of The American Society for Clinical Investigation, a Scholar-Innovator of the Harrington Discovery Institute, a recipient of an AACR Innovation and Discovery award, and a regular member of the NIH study section CMAD and of the Melanoma Research Alliance Grant Review Panel. He serves as Director of the Cancer Biology doctoral program at the University of Michigan. His lab is supported through a combination of NIH, DoD, and foundation awards.